HONG
KONG, Aug. 6, 2024 /PRNewswire/ -- Even with the
ever-changing situation, technological innovation is still the most
critical component for biopharmaceutical companies' long-term
development. This continuous innovation keeps companies up to date
and promotes the evolution of R&D and the success of
commercialization. Recently, Viva Biotech's portfolio companies
have new updates. Keep reading for more details.
Nerio Therapeutics, A Viva Biotech's Portfolio Company, Was
Successfully Acquired by Boehringer Ingelheim for $1.3 Billion
San Diego, California - On
July 29, 2024, Boehringer Ingelheim
announced the addition of an innovative preclinical program with
the acquisition of Nerio Therapeutics Inc. ("Nerio"), which is
invested and incubated by Viva BioInnovator (VBI), for a total of
up to USD 1.3 billion. Boehringer
Ingelheim aims to develop this program as a potential key
centerpiece component for its immuno-oncology portfolio to achieve
its goal of improving cancer patient outcomes.
Dr. Han Dai, Chief Innovation
Officer (CIO) of Viva Biotech and Head of Viva BioInnovator,
stated, "Nerio has successfully leveraged the founding team's
extensive R&D experience in targeting phosphatases to develop
innovative and highly selective PTPN2/N1 phosphatase inhibitors for
tumor immunotherapy. This achievement addresses the challenges of
selectivity and druggability of phosphatase inhibitors. We are
delighted to have invested in and supported Nerio's growth from
proof of concept to preclinical research. The acquisition by
Boehringer Ingelheim is a strong validation of our investment
strategy and the comprehensive post-investment support we provide.
With Boehringer Ingelheim's deep expertise in phosphatases and
tumor immunotherapy, we anticipate accelerated development of
Nerio's pipeline, ultimately delivering greater benefits to
patients."
Apeiron to Expand Investment in Synthetic Lethality Pipeline
After New Phase in Collaboration with Exscientia
San Francisco, USA, and Shanghai,
China - On July 18, 2924,
Apeiron Therapeutics (Apeiron), invested and incubated by Viva
BioInnovator (VBI), announced that it has reached an agreement with
Exscientia plc (NASDAQ: EXAI), granting Exscientia full control
over GTAEXS617 ('617) and all related intellectual property. This
asset is currently in the ELUCIDATE Phase 1/2 clinical trial
stage.
Under the terms of the agreement, Apeiron will receive an
upfront payment of $30 million in
cash and equity, in addition to receiving single digit royalties if
Exscientia or a third party commercializes '617, which could be
worth over $100 million in the
upcoming years.
Full-Life Technologies, SK Biopharmaceuticals Enter Licensing
Agreement for Novel Therapeutic Targeting Multiple Solid
Tumors
Heidelberg, Germany and
Seoul, Korea - On July 17, Full-Life Technologies ("Full-Life"), a
fully integrated global radiotherapeutics company, announced that
it has entered into a license agreement with SK Biopharmaceuticals,
a global biotech company, for exclusive worldwide clinical
research, development, manufacturing, and commercialization rights
to Full-Life's "FL-091" radiopharmaceutical compound targeting
neurotensin receptor 1 (NTSR1) positive cancers.
This licensing deal worth $571.5
million includes an upfront payment, and development and
commercial milestones, separate from royalties. Under the terms of
the agreement, SK Biopharmaceuticals will in-license the
NTSR1-targeting Radionuclide Drug Conjugate (RDC) program FL-091 -
as well as its back-up compounds - aimed at developing and
commercializing it as an innovative anti-cancer drug.
Arthrosi Announces First Patient Dosed in Pivotal Phase 3
Reduce 2 Trial of Lead Compound AR882, and Announces Multiple
Presentations at the European League Against Rheumatism (EULAR)
Congress 2024
San Diego - On June 27, 2024, Arthrosi Therapeutics, Inc.,
invested and incubated by Viva BioInnovator (VBI), is a late-stage
biotechnology company developing a potentially best-in-class,
highly potent and selective next generation URAT1 inhibitor to
reduce serum urate levels, flares and Tophi in patients with gout.
They announced that it has dosed the first patient in REDUCE 2, a
pivotal Phase 3 clinical trial to evaluate reduction of sUA in gout
patients.
During the 2024 European Congress of Rheumatology (EULAR)
Congress held from June 12 to June
15, groundbreaking clinical trial results for AR882, a
global Class 1 new drug jointly developed by Arthrosi and ApicHope
(300723.SZ), were prominently presented by Dr. Robert Keenan, Chief Medical Officer of
Arthrosi, reported the latest data from this study at the
conference (Abstract Number: POS0268). The research showed that in
the 6 to 12-month extension study conducted on patients with tophi,
AR882 demonstrated good safety and tolerability, significantly
reduced serum uric acid (sUA) levels, and exhibited continued
dissolution of tophi and crystal volume. AR882 showed more
significant efficacy and better safety in treating gout patients,
including those with clinically visible and subclinical crystal
deposits.
VivaVision Biotech Enrolls First Subject in VVN001 Phase III
Clinical Trial in China
Wenzhou, China - VivaVision
Biotech, Inc. (hereinafter referred to as "VivaVision"), an
innovative Chinese ophthalmic drug development company incubated
and invested by Viva BioInnovator (VBI), has announced that the
first subject has been successfully enrolled and dosed in the China
Phase III clinical trial of its independently developed innovative
drug for dry eye disease treatment - VVN001 eye drops, a new
generation LFA-1 antagonist.
About Nerio Therapeutics
Nerio Therapeutics, Inc. is a drug discovery and development
company focused on phosphatases, a notoriously difficult class of
potentially high-value therapeutic protein targets. Nerio has
developed novel, potent, and highly selective PTPN2/N1 inhibitors
with excellent drug-like properties. Nerio's first-in-class
PTPN2/N1 inhibitors enhance immune function and sensitize tumors to
pro-inflammatory signals, promoting robust anti-tumor activity.
Nerio was founded by Avalon Ventures and had additional financial
support from a syndicate including Bregua Corporation, Correlation
Ventures, Alexandria Venture Investments and Viva BioInnovator.
Nerio was developed in the Avalon BioVentures accelerator,
benefiting from their resident expertise in early-stage drug
development and comprehensive company support.
About Apeiron Therapeutics
Apeiron is redefining medical discovery, using artificial
intelligence to streamline the drug development process—from target
selection to clinical trials. With strategic locations in the
San Francisco Bay Area and
Shanghai, and significant
partnerships in Europe, Apeiron
integrates talent and cutting-edge technologies spanning multiple
regions. We believe that by pushing the frontiers of biomedical
innovation and engaging talent globally we can create breakthrough
medicines for the highest unmet medical needs.
About Full-Life Technologies
Full-Life Technologies ("Full-Life") is a fully integrated
global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain
for radiopharmaceutical research & development, production
& commercialization to deliver clinical impact for patients.
The Company endeavors to tackle fundamental challenges affecting
radiopharmaceuticals today by pioneering innovative research that
will shape the treatments of tomorrow. We are comprised of a team
of fast-moving entrepreneurs and seasoned scientists with a proven
history of success in the life sciences, alongside radioisotope
research and clinical development. For more information, visit
Full-Life's website at www.full-life.com.
About Arthrosi
Arthrosi Therapeutics, Inc., headquartered in San Diego, CA, is focused on developing AR882,
a potentially best-in-class, highly potent and selective next
generation URAT1 inhibitor to reduce serum urate levels, flares and
Tophi in patients with gout. Gout remains a large and growing
market with ~ 13M patients in the
U.S. alone, ~2M of which have tophaceous gout. AR882 has
demonstrated encouraging efficacy and safety compared to SOC in
Phase 2 studies as well as impressive results in achieving complete
resolution of tophi in a Phase 2b
study. Arthrosi is currently advancing AR882 in a pivotal phase 3
program.
About VivaVision Biotech
VivaVision is a clinical stage pharmaceutical company focused on
best-in-class and first-in-class therapies for ocular diseases.
VivaVision's current pipeline includes VVN001 for treating dry eye
syndrome, VVN539 for the treatment for Glaucoma or Ocular
Hypertension, and VVN461 for the treatment of non-infectious ocular
inflammation of Uveitis. VivaVision is also engaged in discovery
and development of novel therapies for the treatment of other
anterior and posterior eye diseases. For more info, visit
www.vivavisionbio.com.
View original
content:https://www.prnewswire.com/news-releases/latest-updates-of-viva-biotechs-portfolio-companies-302215426.html
SOURCE Viva Biotech Holdings